Three pharmaceutical companies settle with California over deals to keep generic medications off the market

According to the California attorney general’s office, two pharmaceutical companies will pay the state of California a total of nearly $70 million to settle allegations that they violated antitrust laws by making agreements to delay generic drugs. Regulators have said, “Pay-for-delay” agreements – under which the maker of a brand-name drug pays other drugmakers to refrain from producing a generic version after the drug’s patent expires keep drug prices high. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.